[{"id":"aafc6a72-033b-4470-9c1d-5d77ddce9a83","acronym":"","url":"https://clinicaltrials.gov/study/NCT05549921","created_at":"2022-09-22T15:56:31.418Z","updated_at":"2024-07-02T16:35:25.127Z","phase":"Phase 2","brief_title":"Phase II Study of TAEST16001 in Soft Tissue Sarcoma","source_id_and_acronym":"NCT05549921","lead_sponsor":"Sun Yat-sen University","biomarkers":" HLA-A • CTAG1B","pipe":" | ","alterations":" HLA-A*02:01 • HLA-A*02","tags":["HLA-A • CTAG1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02:01 • HLA-A*02"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TAEST16001"],"overall_status":"Recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 07/08/2022","start_date":" 07/08/2022","primary_txt":" Primary completion: 09/01/2024","primary_completion_date":" 09/01/2024","study_txt":" Completion: 09/01/2024","study_completion_date":" 09/01/2024","last_update_posted":"2023-12-27"},{"id":"9f1bb930-90b6-47c8-bc95-d55cb1f1fabb","acronym":"","url":"https://clinicaltrials.gov/study/NCT04318964","created_at":"2021-01-19T19:31:04.586Z","updated_at":"2024-07-02T16:35:50.876Z","phase":"Phase 1","brief_title":"TAEST16001 in the Treatment of Soft Tissue Sarcoma","source_id_and_acronym":"NCT04318964","lead_sponsor":"Sun Yat-sen University","biomarkers":" IL6 • CTAG1B","pipe":"","alterations":" ","tags":["IL6 • CTAG1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TAEST16001"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 03/19/2020","start_date":" 03/19/2020","primary_txt":" Primary completion: 04/15/2022","primary_completion_date":" 04/15/2022","study_txt":" Completion: 05/01/2024","study_completion_date":" 05/01/2024","last_update_posted":"2023-04-12"},{"id":"d924c9a5-111c-4192-ac55-a94b62900700","acronym":"","url":"https://clinicaltrials.gov/study/NCT03462316","created_at":"2021-01-19T15:41:01.893Z","updated_at":"2024-07-02T16:35:50.717Z","phase":"Phase 1","brief_title":"NY-ESO-1-specific T Cell Receptor (TCR) T Cell in Sarcoma","source_id_and_acronym":"NCT03462316","lead_sponsor":"Sun Yat-sen University","biomarkers":" CTAG1B","pipe":"","alterations":" ","tags":["CTAG1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • TAEST16001"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 05/21/2018","start_date":" 05/21/2018","primary_txt":" Primary completion: 02/15/2024","primary_completion_date":" 02/15/2024","study_txt":" Completion: 05/15/2024","study_completion_date":" 05/15/2024","last_update_posted":"2023-04-12"},{"id":"0135e427-b480-4261-8730-c6763eda0474","acronym":"","url":"https://clinicaltrials.gov/study/NCT03159585","created_at":"2021-02-11T07:05:29.812Z","updated_at":"2024-07-02T16:36:51.033Z","phase":"Phase 1","brief_title":"To Evaluate the Efficacy of NY-ESO-1-specific T Cell Receptor Affinity Enhancing Specific T Cell in Solid Tumors","source_id_and_acronym":"NCT03159585","lead_sponsor":"Zhujiang Hospital","biomarkers":" CTAG1B","pipe":"","alterations":" ","tags":["CTAG1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • TAEST16001"],"overall_status":"Completed","enrollment":" Enrollment 6","initiation":"Initiation: 04/14/2017","start_date":" 04/14/2017","primary_txt":" Primary completion: 06/04/2019","primary_completion_date":" 06/04/2019","study_txt":" Completion: 06/04/2019","study_completion_date":" 06/04/2019","last_update_posted":"2020-01-22"},{"id":"d5aa3cc3-f529-4b63-b742-7f0b390e9c98","acronym":"","url":"https://clinicaltrials.gov/study/NCT03029273","created_at":"2021-01-18T14:54:32.246Z","updated_at":"2024-07-02T16:37:03.751Z","phase":"Phase 1","brief_title":"NY-ESO-1 TCR （TAEST16001）for Patients With Advanced NSCLC","source_id_and_acronym":"NCT03029273","lead_sponsor":"Guangzhou Institute of Respiratory Disease","biomarkers":" EGFR • ALK • CTAG1B","pipe":" | ","alterations":" EGFR mutation • ALK rearrangement • CTAG1B expression","tags":["EGFR • ALK • CTAG1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK rearrangement • CTAG1B expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • TAEST16001 • cyclophosphamide intravenous"],"overall_status":"Unknown status","enrollment":" Enrollment 20","initiation":"Initiation: 03/21/2017","start_date":" 03/21/2017","primary_txt":" Primary completion: 03/01/2019","primary_completion_date":" 03/01/2019","study_txt":" Completion: 03/01/2019","study_completion_date":" 03/01/2019","last_update_posted":"2019-01-17"}]